PEPTIDE RESEARCH PUBLICATION TRENDS 2015-2026

For Laboratory Research Use Only. Not for human consumption. This report is a bibliometric snapshot and does not constitute medical advice, a marketing claim, or any statement about the safety or efficacy of any compound.

Annual PubMed publication counts for 17 research peptides across the 2015-2025 window. Free dataset under CC BY 4.0. Data retrieved 2026-05-19 via the NCBI E-Utilities esearch endpoint. Total papers tallied across all compounds and years: 26,557.

WHAT THIS REPORT MEASURES

Publication count is a coarse-but-useful proxy for scientific attention. When a peptide moves from a handful of mechanistic papers per year into the hundreds, that shift reflects three things at once: investigator interest, funding flow, and the saturation of preclinical questions that have to be answered before a compound can credibly enter (or stay inside) clinical pipelines. We track that shift across an 11-year window for 17 compounds that span four functional clusters: incretin and metabolic peptides (the triple-receptor incretin agonist, the GLP-1 / GIP dual agonist), tissue repair and cytoprotection (BPC-157, TB-500, GHK-Cu), mitochondrial and longevity-adjacent compounds (NAD+, MOTS-c, SS-31), and growth-axis or nootropic peptides (tesamorelin, CJC-1295, selank, semax). The mix is meant to capture the working catalogue most research-grade suppliers and chemistry-focused readers actually encounter, not a regulatory or therapeutic ranking.

VISUAL: 11-YEAR TIME-SERIES

Each line is one compound. The X-axis is calendar year of publication and the Y-axis is the count of PubMed records whose title or abstract matched any registered alias for that compound. Hover any point for the exact tally.

TOP 10 FASTEST-GROWING (5-YEAR % GROWTH)

Sorted by percentage change in annual publication count from 2020 → 2025. Compounds with zero 2020 records and a non-zero 2025 count are flagged NEW because no meaningful denominator exists for percentage math.

FULL TIME-SERIES TABLE · 17 COMPOUNDS × 11 YEARS

NOTES ON THE PATTERN

Three patterns are worth highlighting. First, the incretin class (the GLP-1 / GIP dual agonist, the triple-receptor incretin agonist) shows the steepest absolute and percentage gains. the GLP-1 / GIP dual agonist moved from a handful of mechanism-of-action papers in the late 2010s into the largest annual cohort of any peptide in the dataset by 2024-2025, driven by the SURPASS and SURMOUNT trial families and the volume of secondary analyses they generate. the triple-receptor incretin agonist is the same shape one cycle behind: zero records before 2022, then a sharp ramp once the Phase 2 NEJM paper landed. Second, NAD+ sits in a class of its own. It is not a peptide in the narrow sense, but it travels alongside this catalogue in the longevity literature, and the per-year counts (consistently in the hundreds, climbing into four digits) reflect its position as a high-volume substrate-biology topic rather than a single-drug story.

Third, the tissue-repair cluster (BPC-157, TB-500, GHK-Cu) grows steadily but at a much smaller absolute scale. These compounds attract sustained preclinical interest, particularly from gastric, tendon, and dermal research groups, but very little of that work has graduated into registered human trials. The contrast between the incretin curve (industrial trial pipeline) and the tissue-repair curve (academic preclinical work) is the cleanest illustration of how publication volume tracks funding shape, not therapeutic promise. The newer compounds (5-Amino-1MQ, MOTS-c, KLOW Blend, Wolverine Blend) sit on small bases with high percentage growth. Treat percentage figures on small denominators with caution: a jump from three papers to thirty looks dramatic but reflects a different research stage than the incretin curve.

METHODOLOGY

PubMed E-Utilities esearch query template: (<alias1>[Title/Abstract] OR <alias2>[Title/Abstract]) AND <year>[Date - Publication]. Aliases are joined with OR so a paper using any registered name for the compound is counted (for example BPC-157 OR PL14736 OR “Body Protection Compound 157”).

Retrieval date: 2026-05-19.
Endpoint: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi
Inclusion criteria: any record indexed in PubMed whose title or abstract matches an alias for the compound, with a publication date inside the calendar year. Pre-prints from bioRxiv and medRxiv are excluded because PubMed does not index them. Errata, retractions, and conference abstracts indexed in PubMed are included because the API does not separate them cleanly from primary articles.

Limitations: PubMed indexing lags real publication by several weeks for some journals; the 2025 count will undercount slightly until early 2026. Compound aliases that overlap with unrelated chemistry (notably very short codes) may include false positives; the alias list is hand-curated to minimize this. Total counts are sensitive to alias-set choices; the alias set used for this regeneration is recorded in the regeneration script in the source repository.

Update cadence: quarterly. The regeneration script lives at scripts/refresh-research-trends.mjs and writes the canonical JSON consumed by this page.

CITE THIS REPORT

Cite this report: GigaCompounds LLC. Peptide Research Publication Trends 2015-2026. Retrieved 2026-05-19 from gigaresearch.vercel.app/reports/peptide-research-publication- trends-2015-2026

RELATED

• Regulatory Status Matrix · 17 Peptides × 10 Countries
• GIGARESEARCH home · the full 17-peptide index